Overall, both chromosomal rearrangements and mutations of VAV1 lead to the constitutive activation of VAV1 effector pathways, including the RHO GTPase RAC1, supporting a driver role for VAV1 in the pathogenesis of PTCL. Here, VAV1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.